Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 5/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CPT1A | P50416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21150809 | 0.86 | ACHE (0.48) | KDM4EALDH1A1TDP1SMN1; SMN2TP53 | |
| SCHEMBL21152121 | 0.86 | ALDH1A1 (0.52) | KDM4EALDH1A1TDP1SMN1; SMN2TP53 | |
| SCHEMBL21151289 | 0.86 | ACHE (0.44) | KDM4EALDH1A1TDP1SMN1; SMN2TP53 | |
| SCHEMBL21150807 | 0.84 | ACHE (0.53) | KDM4EALDH1A1TDP1SMN1; SMN2TP53 | |
| SCHEMBL21150805 | 0.74 | YAP1 (0.46) | KDM4EALDH1A1SMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL21150798 | 0.70 | GPR119 (0.57) | KDM4ETP53MAPTPOLB | |
| SCHEMBL6949563 | 0.68 | FFAR1 (0.65) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL14578661 | 0.65 | ALDH1A1 (0.78) | KDM4EALDH1A1TDP1SMN1; SMN2TP53 | |
| SCHEMBL29590229 | 0.64 | GRM4 (0.48) | ALDH1A1TDP1SMN1; SMN2TP53L3MBTL1 | |
| SCHEMBL21150757 | 0.63 | ALDH1A1 (0.39) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | KDM4E 2126/4885ALDH1A1 1203/4885TDP1 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.